Abstract
Treatment with lower extremity intermittent negative pressure (INP) of -40 mm Hg for one hour twice daily for 12 weeks, increases walking capacity in patients with intermittent claudication (IC). However, the effects of INP treatment beyond 12 weeks have not been elucidated. The aim of the present study was to investigate the clinical effects of INP treatment after 24 weeks in patients with IC. This was a follow-up study after a randomized sham-controlled trial, where patients randomized to the active treatment group were offered to continue treatment for 12 additional weeks (24 weeks in total). Treatment with -40 mm Hg INP was applied in a pressure chamber sealed around the lower leg, and the patients were instructed to treat themselves at home one hour in the morning and one hour in the evening. Pain free walking distance (PWD), maximal walking distance (MWD), resting ankle-brachial index (ABI) and post exercise ABI were measured at baseline, after 12 and 24 weeks. Ten out of 32 patients (31%) from the active treatment group in the initial trial were included in this follow-up study. At baseline, PWD was (mean ±SD) 151 ± 91 m and MWD was 362 ±159 m. There was a significant increase in both PWD and MWD after 24 weeks of treatment, compared to baseline (ANOVA; P= 0.006 and P= 0.012, respectively). Post hoc tests revealed that PWD increased significantly from baseline to 12 weeks (mean 81 m; 95% CI [6, 156]; P = 0.032), and that MWD increased significantly from 12 to 24 weeks (mean 145 m; 95% CI [22, 268]; P = 0.018). There were no significant changes in resting ABI or post exercise ABI during the 24-week treatment period (ANOVA; P= 0.157 and P= 0.450, respectively). Both PWD and MWD improved after treatment with - 40 mm Hg INP for one hour twice daily for 24 weeks, compared to baseline. The main improvement in PWD occurred during the first 12 weeks of treatment, whereas the main improvement in MWD occurred between 12 and 24 weeks of treatment.
Highlights
Peripheral artery disease (PAD) is associated with significant morbidity, increased mortality, and decreased quality of life
In a recent double-blind randomized sham-controlled trial from our research group, we found that treatment with lower extremity intermittent negative pressure (INP) one hour twice daily for 12 weeks increased walking capacity in patients with intermittent claudication (IC) compared to sham treatment.[12]
Pain free walking distance (PWD), maximal walking distance (MWD), resting ankle-brachial index (ABI), and post exercise ABI were measured at baseline, at 12 weeks and at 24 weeks of INP treatment
Summary
Peripheral artery disease (PAD) is associated with significant morbidity, increased mortality, and decreased quality of life. Lower extremity intermittent negative pressure (INP) treatment increases blood flow, reduces leg symptoms and has been suggested as a treatment option for patients with PAD in several studies.[6,7,8,9,10,11,12] In a recent double-blind randomized sham-controlled trial from our research group, we found that treatment with lower extremity INP one hour twice daily for 12 weeks increased walking capacity in patients with IC compared to sham treatment.[12] the potential clinical effects of continued INP treatment beyond 12 weeks have not been elucidated. Conclusion: Both PWD and MWD improved after treatment with – 40 mm Hg INP for one hour twice daily for 24 weeks, compared to baseline. The main improvement in PWD occurred during the first 12 weeks of treatment, whereas the main improvement in MWD occurred between 12 and 24 weeks of treatment
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
